Plasma concentration profiles of ketamine and norketamine after administration of various ketamine preparations to healthy Japanese volunteers

Biopharmaceutics and Drug Disposition

Volumn 24, Issue 1, 2003, Pages 37-43

  Yanagihara, Yoshitsugu ^a,b   Ohtani, Michiteru ^b   Kariya, Satoru ^b   Uchino, Katsuyoshi ^b   Hiraishi, Teiko ^b   Ashizawa, Naofumi ^b   Aoyama, Takao ^a   Yamamura, Yoshikazu ^a   Yamada, Yasuhiko ^a   Iga, Tatsuji ^a  

^a UNIVERSITY OF TOKYO   (Japan)

^b Tokyo Postal Services Agency Hospital   (Japan)

Author keywords

Analgesic; Ketamine; Norketamine; Plasma concentration; Preparation

Indexed keywords

DRUG METABOLITE; KETAMINE; NORKETAMINE; NOSE SPRAY; UNCLASSIFIED DRUG; VOSCO;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE ACTIVITY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; ENANTIOMER; HUMAN; HUMAN EXPERIMENT; INTERMETHOD COMPARISON; JAPAN; MALE; NEUROPATHIC PAIN; NORMAL HUMAN; SUPPOSITORY; TABLET FORMULATION; VOLUNTEER;

ADMINISTRATION, INTRANASAL; ADULT; ANALYSIS OF VARIANCE; AREA UNDER CURVE; CHEMISTRY, PHARMACEUTICAL; HUMANS; KETAMINE; MALE; STEREOISOMERISM; VAGINAL CREAMS, FOAMS, AND JELLIES;

EID: 0037245080     PISSN: 01422782     EISSN: None     Source Type: Journal    
DOI: 10.1002/bdd.336     Document Type: Article

References (17)

1. White PF, Way WL, Trevor AJ. Ketamine-its pharmacology and therapeutic uses. Anesthesiology 1982; 56: 119-36.
2. Reich DL, Silvay G. Ketamine: an update on the first twenty-five years of clinical experience. Can J Anaesth 1989; 36: 186-97.
3. Eide PK, Stubhaug A, Øye I, Breivik H. Continuous subcutaneous administration of the N-methyl-D-aspartic acid (NMDA) receptor antagonist ketamine in the treatment of post-herpetic neuralgia. Pain 1995; 61: 221-8.
4. Nikolajsen L, Hansen PO, Jensen TS. Oral ketamine therapy in the treatment of postamputation stump pain. Acta Anaesthesiol Scand 1997; 41: 427-29.
5. Broadley KE, Kurowska K, Tookman A. Ketamine injection used orally. Palliat Med 1996; 10: 247-50.
6. Mathisen LC, Skjelbred P, Skoglund LA, Øye I. Effect of ketamine, an NMDA receptor inhibitor, in acute and chronic orofacial pain. Pain 1995; 61: 215-20.
7. Shimoyama M, Shimoyama N, Gorman AL, Elliott KJ, Inturrisi CE. Oral ketamine is antinociceptive in the rat formalin test: role of the metabolite, norketamine. Pain 1999; 81: 85-93.
8. Grant IS, Nimmo WS, Clements JA. Pharmacokinetics and analgesic effects of i.m. and oral ketamine. Br J Anaesth 1981; 53: 805-10.
9. Clements JA, Nimmo WS. Pharmacokinetics and analgesic effect of ketamine in man. Br J Anaesth 1981; 53: 27-31.
10. Geisslinger G, Hering W, Thomann P, Knoll R, Kamp HD, Brune K. Pharmacokinetics and pharmacodynamics of ketamine enantiomers in surgical patients using a stereo-selective analytical method. Br J Anaesth 1993; 70: 666-71.
11. Idvall J, Ahlgren I, Aronsen F, Stenberg P. Ketamine infusions: pharmacokinetics and clinical effects. Br J Anaesth 1979; 51: 1167-73.
12. White PF, Schuttler J, Shafer A, Stanski DR, Horai Y, Trevor AJ. Comparative pharmacology of the ketamine isomers. Br J Anaesth 1985; 57: 197-203.
13. Wieber J, Gugler R, Hengstmann JH, Dengler HJ. Pharmacokinetics of ketamine in man. Anaesthesist 1975; 24: 260-63.
14. Malinovsky J-M, Servin F, Cozian A, Lepage JY, Pinaud M. Ketamine and norketamine plasma concentrations after i.v., nasal and rectal administration in children. Br J Anaesth 1996; 77: 203-7.
15. Yanagihara Y, Ohtani M, Kariya S, et al. Preparation of ketamine tablets for treatment of patients with neuropathic pain. Yakugaku Zasshi 1999; 119: 980-7.
16. Yanagihara Y, Ohtani M, Kariya S, et al. Stereoselective high-performance liquid chromatographic (HPLC) determination of ketamine and its active metabolite, norketamine, in human plasma. J Chromatogr 2000; 746: 227-31.
17. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. A pharmacokinetics analysis program (MULTI) for microcomputer. J Pharmacobio-Dyn 1981; 4: 879-85.